766 related articles for article (PubMed ID: 20828280)
1. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
2. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C
Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
[TBL] [Abstract][Full Text] [Related]
3. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
4. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
Chovel-Sella A; Karplus R; Sella T; Amital H
Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
[TBL] [Abstract][Full Text] [Related]
6. Golimumab (simponi) for inflammatory arthritis.
Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
[No Abstract] [Full Text] [Related]
7. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
8. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
9. Golimumab - a new tool in the armoury against inflammatory arthritis.
Ash Z; Emery P
Ann Med; 2011 Mar; 43(2):133-41. PubMed ID: 21244218
[TBL] [Abstract][Full Text] [Related]
10. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
[TBL] [Abstract][Full Text] [Related]
11. Golimumab, the newest TNF-α blocker, comes of age.
Papagoras C; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2015; 33(4):570-7. PubMed ID: 25602858
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
[TBL] [Abstract][Full Text] [Related]
13. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Poddubnyy D; Rudwaleit M
Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
[TBL] [Abstract][Full Text] [Related]
15. "Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?".
Fiocco U; Punzi L
Joint Bone Spine; 2011 Jul; 78(4):331-4. PubMed ID: 21353617
[No Abstract] [Full Text] [Related]
16. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
17. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
[TBL] [Abstract][Full Text] [Related]
18. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
Biggioggero M; Favalli EG
Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
[TBL] [Abstract][Full Text] [Related]
19. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of golimumab in the treatment of arthritis.
Fleischmann R
Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
